eFFECTOR Therapeutics, Inc. Profile Avatar - Palmy Investing

eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of…

Biotechnology
US, Solana Beach [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

eFFECTOR Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of EFTR's Analysis
CIK: 1828522 CUSIP: 28202V108 ISIN: US28202V2079 LEI: - UEI: -
Secondary Listings
EFTR has no secondary listings inside our databases.